Treatment Overview
Immunotherapy in India has become an important part of modern cancer treatment. Instead of directly killing cancer cells in the same way as conventional chemotherapy, many immunotherapies help the body's immune system recognise, attack or control cancer cells.
Immunotherapy is not a single medicine or treatment. It includes several approaches, such as immune checkpoint inhibitors, monoclonal antibodies, CAR T-cell therapy, T-cell transfer therapies, cancer treatment vaccines and immune-system modulators. The appropriate treatment depends on the cancer type, stage, molecular characteristics, previous treatments, overall health and the specific indication for the drug.
There is a named GAF Healthcare partner planning sheet for immunotherapy: $15,000–$45,000, typically Outpatient q2–6 weeks. Neighbouring United States comparison figures on the same sheet are $100,000–$250,000. That India band is a pathway planning range for oncology review, a named checkpoint or antibody medicine and associated monitoring. It is not the price of a single infusion and it is not a whole-cancer package.
Neighbouring immune checkpoint inhibitor therapy is $18,000–$50,000, typically Outpatient infusions q2–6 weeks. Neighbouring CAR-T cell therapy is $80,000–$180,000, typically Apheresis + 3–6 weeks nearby. Neighbouring dendritic cell therapy is $8,000–$22,000. Neighbouring chemotherapy is $1,500–$8,000+. Neighbouring targeted therapy is $8,000–$30,000. Neighbouring precision oncology is $2,000–$7,000. Neighbouring hormone therapy is $1,000–$4,500.
Disease pathways sit on breast cancer treatment in India, colon cancer treatment in India, cervical cancer treatment in India, prostate cancer treatment in India, ovarian cancer treatment in India, leukemia treatment in India and lymphoma treatment in India. Neighbouring medicine lists sit on targeted therapy in India, molecular targeted therapy in India, precision oncology in India and hormone therapy in India. Cellular neighbours sit on CAR-T cell therapy in India and dendritic cell therapy in India. There is no live GAF lung-cancer-only, melanoma-only, kidney-cancer-only, bladder-cancer-only, liver-cancer-only, gastric-cancer-only or head-and-neck-cancer-only treatment page.
Important: Immunotherapy is not automatically appropriate simply because a cancer is advanced. The treatment needs to match the patient's cancer, biomarker, previous treatments, overall health and the evidence supporting the particular drug. A quotation should be obtained only after records review.
What is immunotherapy for cancer?
Immunotherapy is a type of biological cancer treatment that uses or modifies components of the immune system to help fight cancer.
Your immune system naturally identifies abnormal cells and can destroy some cancer cells. Cancer can develop mechanisms that allow it to avoid immune attack. Cancer cells may alter their appearance, suppress immune responses or create a tumour environment that makes it difficult for immune cells to work effectively.
Immunotherapy attempts to overcome some of these mechanisms.
One of the best-known examples is immune checkpoint inhibition. Immune checkpoints normally prevent the immune system from becoming excessively active. Cancer cells can exploit these mechanisms to avoid destruction.
Checkpoint inhibitor medicines interfere with these inhibitory signals. Medicines targeting PD-1, PD-L1 or CTLA-4 can allow T cells to remain active against cancer cells.
This does not mean that every cancer responds to immunotherapy. The biology of the tumour matters.
How does immunotherapy work?
The immune system contains several types of cells and proteins that work together to recognise abnormal cells.
T cells are particularly important because they can identify and destroy cells carrying abnormal or foreign signals. Cancer can interfere with this process.
Interaction between PD-1 on T cells and PD-L1 on tumour or other cells can send an inhibitory signal to the T cell. Some tumours exploit this pathway to reduce immune attack.
A PD-1 or PD-L1 inhibitor can block that interaction and help restore T-cell activity. CTLA-4 inhibitors work through a different checkpoint pathway.
Other forms of immunotherapy use different mechanisms. CAR T-cell therapy involves collecting a patient's T cells, modifying them so they express a chimeric antigen receptor, expanding the cells and infusing them back. Named cellular lists sit on CAR-T cell therapy in India.
This is why the term “immunotherapy” should not be treated as synonymous with one particular drug.
Types of immunotherapy
Immune checkpoint inhibitors
Checkpoint inhibitors are among the most widely used forms of modern cancer immunotherapy. They target immune-regulating proteins such as PD-1, PD-L1, CTLA-4 and LAG-3.
Examples include pembrolizumab, nivolumab, atezolizumab, durvalumab, ipilimumab and relatlimab-containing combinations. The exact drug depends on the cancer type, stage, biomarker profile and treatment indication.
Checkpoint inhibitors can be used alone or combined with chemotherapy, targeted therapy, radiation or another immunotherapy in selected situations. Neighbouring checkpoint planning on this site is $18,000–$50,000.
Monoclonal antibodies
Monoclonal antibodies are laboratory-produced proteins designed to bind to specific targets. Some help the immune system recognise and destroy cancer cells. Others are better classified primarily as targeted therapies. Named lists sit on targeted therapy in India.
Patients sometimes hear “antibody treatment” and assume that every antibody is an immunotherapy. The mechanism and indication need to be assessed individually.
CAR T-cell therapy
CAR T-cell therapy is an advanced form of cellular immunotherapy. The process generally involves collecting T cells, laboratory processing, genetic modification, expansion, preparing the patient, infusion and close monitoring.
It has particular importance in some blood cancers, including selected B-cell malignancies. It is different from standard checkpoint inhibitor therapy and requires specialised infrastructure. Named lists sit on CAR-T cell therapy in India. GAF planning is $80,000–$180,000, typically Apheresis + 3–6 weeks nearby.
TIL and other T-cell transfer therapies
T-cell transfer therapy involves using immune cells to strengthen the immune response against cancer. One approach is tumour-infiltrating lymphocyte (TIL) therapy. Availability and approved indications vary by country and cancer type.
Cancer treatment vaccines and dendritic-cell programmes
Cancer treatment vaccines are different from vaccines designed to prevent infections. Their purpose is to stimulate an immune response against cancer. Named autologous lists sit on dendritic cell therapy in India.
Immune-system modulators
Some medicines influence the activity of the immune system more broadly. Commercially marketed supplements and “immune boosters” are not equivalent to evidence-based cancer immunotherapy.
Which cancers can be treated with immunotherapy?
Immunotherapy is now used across multiple cancer types, but its role differs substantially between cancers.
Lung cancer. Checkpoint inhibitors may be used alone or with chemotherapy depending on subtype, stage and biomarker results. There is no live GAF lung-cancer-only treatment page.
Melanoma. Checkpoint inhibitors have become particularly important. Combination immunotherapy can increase immune-related toxicity. There is no live GAF melanoma-only treatment page.
Kidney cancer. Immune checkpoint inhibitors are used in selected patients with renal-cell carcinoma. There is no live GAF kidney-cancer-only treatment page.
Bladder and urothelial cancer. Immunotherapy can be used in selected patients. There is no live GAF bladder-cancer-only treatment page.
Head and neck cancer. Checkpoint inhibitors are used in selected advanced disease. There is no live GAF head-and-neck-cancer-only treatment page.
Colorectal cancer. Immunotherapy is particularly relevant to mismatch-repair-deficient (dMMR) and microsatellite-instability-high (MSI-H) disease. See colon cancer treatment in India and colon cancer immunotherapy.
Breast cancer. Immunotherapy has a role in selected settings, particularly some forms of triple-negative breast cancer. See breast cancer treatment in India.
Cervical cancer. Checkpoint inhibitors may be used in selected patients. See cervical cancer treatment in India.
Liver cancer. Immunotherapy has become an important component of systemic treatment for selected hepatocellular carcinoma. There is no live GAF liver-cancer-only treatment page.
Stomach and gastroesophageal cancers. Immunotherapy can be used for selected gastric cancers. There is no live GAF gastric-cancer-only treatment page.
Hodgkin lymphoma and other blood cancers. Checkpoint inhibitors and other immunotherapies can be used in selected lymphomas. CAR T-cell therapy has become important for selected relapsed or refractory blood cancers. See lymphoma treatment in India and leukemia treatment in India.
Biomarker testing before immunotherapy
One of the most important parts of modern immunotherapy treatment is patient selection.
Depending on the cancer, testing can include PD-L1 expression, MSI status, MMR status, tumour mutational burden in selected settings, specific genetic alterations and cancer-specific pathology markers.
Not every patient needs every test. For some cancers, PD-L1 can influence treatment selection. In others, MSI-H or dMMR status can be particularly important.
Named testing lists sit on precision oncology in India. A pathology review is an important part of treatment planning.
What happens before immunotherapy?
- Confirm the cancer diagnosis through pathology.
- Determine the stage with imaging and other investigations.
- Review previous chemotherapy, radiation, surgery, targeted therapy or immunotherapy.
- Decide which biomarkers should be tested.
- Assess kidney function, liver function, blood counts and general health.
- Review autoimmune disease, organ dysfunction and other medical conditions.
- Discuss benefits, risks, schedule, alternatives and monitoring.
How is immunotherapy given?
Many checkpoint inhibitors are administered as an intravenous infusion in an oncology day-care unit rather than requiring an overnight hospital stay.
The interval between treatments depends on the drug and indication. Some regimens are administered every few weeks, while others use longer intervals.
The treatment plan should specify the drug name, dose, route, frequency, number of planned cycles, treatment intent, monitoring requirements and conditions for continuing or stopping treatment.
CAR T-cell therapy is not a day-care checkpoint infusion. It requires apheresis, manufacturing and weeks nearby. See CAR-T cell therapy in India.
Immunotherapy versus chemotherapy
Immunotherapy and chemotherapy are different types of cancer treatment.
| Feature | Immunotherapy | Chemotherapy |
|---|---|---|
| Main principle | Helps the immune system recognise or attack cancer | Uses cytotoxic medicines to damage or kill rapidly dividing cells |
| Selectivity | Depends on the immunotherapy and tumour biology | Often affects rapidly dividing normal cells as well as cancer cells |
| Biomarkers | Important for some immunotherapies | Depends on the cancer and regimen |
| Common side effects | Immune-related inflammation, fatigue, rash and endocrine effects | Nausea, fatigue, hair loss and blood-count changes can occur, depending on drugs |
| Timing of toxicity | Can occur during or after treatment | Often related to treatment cycles, but varies |
| Treatment combinations | May be combined with chemotherapy or other treatments | Frequently combined with surgery, radiation, targeted therapy or immunotherapy |
Neither treatment can simply be described as universally better. Neighbouring cytotoxic lists sit on adjuvant chemotherapy in India and neoadjuvant chemotherapy in India. Named chemotherapy lists sit on Chemotherapy in India.
Immunotherapy versus targeted therapy
Targeted therapy aims to interfere with specific molecular abnormalities or proteins that help cancer grow or survive. Immunotherapy aims to involve or modify the immune response against cancer.
There can be overlap because some monoclonal antibodies have both targeted and immune-mediated effects. Named lists sit on targeted therapy in India.
A modern cancer treatment plan may combine surgery, chemotherapy, radiation, immunotherapy and targeted therapy. The combination is determined by the cancer type, stage and available evidence.
Side effects of immunotherapy
Immunotherapy does not cause exactly the same side effects as chemotherapy. Because checkpoint inhibitors activate or restore immune activity, they can sometimes cause the immune system to attack healthy tissues. These are called immune-related adverse events (irAEs). They can affect almost any organ.
Common or clinically important immune-related effects include skin rash, itching, fatigue, diarrhoea, colitis, hepatitis, pneumonitis, thyroid disorders, adrenal insufficiency, pituitary inflammation, kidney inflammation, joint inflammation, neurological complications and cardiac inflammation.
Some effects are mild, while others can become serious or life-threatening if not identified early.
New or worsening breathlessness, persistent or severe diarrhoea, blood in stool, severe abdominal pain, yellowing of the skin or eyes, chest pain, confusion, high fever or a rapidly worsening rash belongs in a local emergency department immediately. Do not wait for the next clinic appointment or use WhatsApp as emergency care.
Fatigue, rash and diarrhoea
Fatigue is commonly reported. Severe or worsening fatigue should not automatically be attributed to cancer or treatment. The team may investigate thyroid, adrenal, blood or other abnormalities.
Rashes and itching can occur because of immune activation. Persistent or significant diarrhoea can indicate immune-mediated inflammation of the bowel and should be reported promptly.
Thyroid problems and pneumonitis
Immunotherapy can affect hormone-producing organs. Thyroid dysfunction may cause fatigue, weight changes, feeling unusually hot or cold, palpitations or changes in bowel habits. Some endocrine effects may require long-term hormone replacement.
Inflammation of the lungs is an uncommon but potentially serious complication. Symptoms can include a new cough, breathlessness, chest discomfort or reduced oxygen levels.
Side effects after treatment ends
Some immune-related side effects can occur after treatment has finished. This is one reason patients should tell future healthcare providers that they have previously received immunotherapy. Patients should retain their oncology treatment records, including the name of the immunotherapy medicine and dates of administration.
How effective is immunotherapy?
The effectiveness of immunotherapy varies considerably. Some patients have substantial tumour shrinkage or long-lasting disease control. Others have little or no response. Some initially respond and later develop acquired resistance.
The likelihood of benefit depends on cancer type, stage, tumour biology, biomarker status, previous treatment, overall health, the immune environment around the tumour and the specific immunotherapy used.
There is no single immunotherapy success rate. Studies may measure overall response rate, complete response, partial response, progression-free survival, overall survival, duration of response or disease control rate. A 20% response rate does not mean that 20% of patients are cured.
Ask: “For patients with my exact cancer type, stage and biomarker profile, what benefit has this treatment shown in clinical studies?”
Immunotherapy cost in India
The cost of immunotherapy in India varies substantially. There is no single price because immunotherapy includes different medicines and cellular treatments.
GAF Healthcare partner planning for immunotherapy is $15,000–$45,000, typically Outpatient q2–6 weeks. Neighbouring United States comparison figures are $100,000–$250,000. Neighbouring immune checkpoint inhibitor therapy is $18,000–$50,000. Neighbouring CAR-T cell therapy is $80,000–$180,000. Neighbouring dendritic cell therapy is $8,000–$22,000.
Major factors include the type of immunotherapy, brand or biosimilar, dose, body weight where applicable, number of vials, treatment frequency, number of cycles, hospital or day-care charges, blood tests, imaging, biomarker testing, management of side effects and whether chemotherapy or targeted therapy is given simultaneously.
| Component | Possible cost component |
|---|---|
| Oncology consultation | Initial and follow-up consultations |
| Biomarker testing | PD-L1, MSI/MMR or other assays |
| Immunotherapy medicine | Usually the largest variable component |
| Infusion / day-care | Applicable to intravenous treatments |
| Blood tests | Monitoring during treatment |
| Imaging | CT, MRI, PET-CT or other scans |
| Supportive medicines | Depending on treatment |
| Management of irAEs | Steroids or hospital care if required |
| Follow-up | Continuing oncology monitoring |
A personalised quotation should be prepared only after reviewing the patient’s diagnosis, pathology, biomarkers and proposed treatment regimen. Patients should not select an immunotherapy simply because it is cheaper. The oncologist should first determine which medicine is medically appropriate.
Immunotherapy cost by Indian city
There is no reliable single national tariff. GAF Healthcare uses one national partner planning band of $15,000–$45,000 rather than inventing city-specific prices.
International patients comparing medical oncologists listing Immunotherapy commonly start with Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. Partner medical oncology hospitals in Delhi NCR, Mumbai and Bengaluru, and in Chennai and Hyderabad, are a typical first filter. City sheets include Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. Pune, Kolkata, Ahmedabad, Kochi, Jaipur, Chandigarh, Lucknow and Varanasi are not live GAF catalog cities on this site.
| City | Catalogue doctors list | India planning band |
|---|---|---|
| Delhi NCR | Medical oncologists listing Immunotherapy | $15,000–$45,000 |
| Mumbai | Medical oncologists listing Immunotherapy | $15,000–$45,000 |
| Bengaluru | Medical oncologists listing Immunotherapy | $15,000–$45,000 |
| Chennai | Medical oncologists listing Immunotherapy | $15,000–$45,000 |
| Hyderabad | Medical oncologists listing Immunotherapy | $15,000–$45,000 |
Why patients consider India
India has a large oncology ecosystem covering medical oncology, surgical oncology, radiation oncology, haematology, bone-marrow transplantation, cellular therapy, molecular pathology, PET-CT and advanced imaging, clinical trials and supportive care.
GAF Healthcare coordinates named partner programmes in Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. The appropriate centre depends on the cancer type, biomarker and treatment complexity rather than city alone.
For international patients, the ability to coordinate several specialties under one cancer-care programme can be an important consideration.
How to choose a cancer centre for immunotherapy
There is no single hospital that is universally right for every immunotherapy patient. Rather than choosing a hospital solely on the basis of an advertised success rate, evaluate whether the centre has the appropriate expertise for the particular cancer.
Consider medical-oncology expertise in the specific cancer, pathology and molecular testing, multidisciplinary cancer care, emergency support for serious treatment complications, cellular-therapy capability if CAR T-cell treatment is being considered, financial transparency and international-patient support.
Hospital selection should therefore be cancer-specific and biomarker-specific rather than based solely on hospital reputation.
Immunotherapy for international patients coming to India
An international patient considering immunotherapy should ideally send histopathology, biopsy and immunohistochemistry reports, molecular or biomarker reports, CT/MRI/PET-CT reports, previous treatment summaries, chemotherapy and radiation records, previous immunotherapy details, a current medication list, relevant blood reports and passport details for administrative processing where required.
The treating oncologist can then determine whether the patient appears suitable for an in-person consultation and whether additional tests are required.
The medical-tourism question is usually not how to stay in India for every infusion indefinitely. It is how to obtain a validated plan, begin safely and transfer monitoring home.
Immunotherapy treatment process in India
- Medical-record review
- Pathology confirmation
- Biomarker testing
- Staging
- Treatment planning
- Cost estimation for the named medicine and expected cycles
- Treatment according to the prescribed schedule
- Monitoring for response and adverse events
- Response assessment
- Continuation, pause, modification or stopping based on response and tolerance
Combination treatment and resistance
Immunotherapy may be combined with chemotherapy, radiation therapy, surgery, targeted therapy, hormone therapy or another immunotherapy agent. Neighbouring radiation lists include external beam radiotherapy in India.
Combinations can improve effectiveness in appropriate patients but may also increase toxicity.
Resistance can be primary (no response from the beginning) or acquired (initial response then later growth). When immunotherapy stops working, the oncologist may consider another systemic therapy, targeted therapy, chemotherapy, radiation, surgery or a clinical trial.
Questions to ask your oncologist
- What type of immunotherapy are you recommending?
- What is the goal of treatment?
- Is my cancer known to respond to this medicine?
- Do I need PD-L1 testing?
- Do I need MSI/MMR testing?
- Are there other biomarkers I should test?
- Will I receive immunotherapy alone or with chemotherapy?
- How often will I receive treatment?
- How many cycles are expected?
- How will we know whether treatment is working?
- What side effects should make me seek urgent care?
- Could side effects occur after treatment ends?
- What is the estimated cost per cycle and what is excluded?
- Is there an appropriate biosimilar option?
- What happens if the cancer progresses?
- Are there clinical trials that may be relevant?
Frequently asked questions
Is immunotherapy better than chemotherapy?
There is no universal answer. Some cancers respond particularly well to immunotherapy, while chemotherapy remains essential for many cancers. In other situations, the two are deliberately combined.
Is immunotherapy available in India?
Yes. A range of immunotherapies is used in India, including checkpoint inhibitors and other antibody-based treatments. Selected specialist centres also provide cellular therapies such as CAR T-cell treatment.
How much does immunotherapy cost in India?
GAF Healthcare partner planning is $15,000–$45,000, typically Outpatient q2–6 weeks. Neighbouring United States comparison figures are $100,000–$250,000. Neighbouring CAR-T cell therapy is $80,000–$180,000. Actual costs depend on the medicine, dose, brand, number of cycles and hospital.
How many cycles of immunotherapy are needed?
There is no standard number. The number of cycles depends on the medicine, cancer type, treatment intent, response and tolerance.
Can immunotherapy completely remove cancer?
It can produce complete responses in some patients, but this does not happen in everyone. The possibility of complete or durable response depends strongly on cancer type, stage and tumour biology.
Can immunotherapy cure stage 4 cancer?
Some patients with advanced cancer can experience long-lasting disease control or complete responses. Stage 4 cancer is not automatically curable with immunotherapy.
Is immunotherapy painful?
The infusion itself is generally not described as a painful treatment, although IV placement can cause temporary discomfort. Side effects may develop during or after treatment.
Does immunotherapy cause hair loss?
Hair loss is generally not the defining side effect of checkpoint immunotherapy in the way it can be with some chemotherapy regimens. Side effects vary by drug and combination treatment.
Can immunotherapy cause fever?
It can. Fever may have several causes, including treatment-related immune effects or infection. A new or significant fever during cancer treatment should be discussed promptly with the oncology team. High fever with collapse belongs in a local emergency department.
Can immunotherapy damage the liver or thyroid?
Yes. Immune-mediated hepatitis and thyroid dysfunction are recognised potential complications. Liver-function and thyroid tests are commonly monitored. Some patients may require long-term thyroid hormone replacement.
Is CAR T-cell therapy the same as immunotherapy?
CAR T-cell therapy is a type of cellular immunotherapy. Unlike checkpoint inhibitors, it uses the patient's T cells, modifies them in a laboratory and returns them. Named lists sit on CAR-T cell therapy in India.
When should I go to an emergency department?
New or worsening breathlessness, persistent or severe diarrhoea, chest pain, confusion, yellowing of the skin, high fever or a rapidly worsening rash belongs in a local emergency department. Do not use WhatsApp as emergency care.
Can international patients receive immunotherapy in India?
Yes, after records review. Feasibility depends on the cancer, biomarker, medicine availability and a plan for continuing infusions or monitoring at home.
Which city in India is right?
There is no single preferred city. Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad are live GAF catalog cities. Confirm the campus that can prescribe the named medicine and manage immune-related complications.
Is immunotherapy available for children?
Some immunotherapies and cellular therapies are used in paediatric cancers, but eligibility depends on the specific cancer, age, treatment indication and regulatory approval.
What if immunotherapy stops working?
The oncologist may consider another systemic therapy, targeted therapy, chemotherapy, radiation, surgery or a clinical trial depending on the circumstances.
Immunotherapy in India: key takeaways
- Immunotherapy is a group of cancer treatments, not one medicine.
- Checkpoint inhibitors are among the most widely used forms.
- PD-1, PD-L1 and CTLA-4 are important immune checkpoints targeted by established therapies.
- Biomarkers can be crucial for treatment selection.
- CAR T-cell therapy is a specialised form of cellular immunotherapy with a separate GAF sheet.
- Immune-related side effects can affect almost any organ and can appear after treatment has ended.
- There is no universal immunotherapy success rate.
- GAF Healthcare partner planning is $15,000–$45,000, typically Outpatient q2–6 weeks.
- Live GAF catalog cities are Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad.
- Severe symptoms belong in a local emergency department, not on WhatsApp.
Final word
If you are considering cancer immunotherapy in India, the first step is not choosing a medicine based on its name or price. The first step is a specialist oncology assessment.
Your treatment team should review your pathology, stage, previous treatment, biomarkers, general health and treatment objectives before recommending a specific immunotherapy.
For international patients, sending the complete medical record before travelling can help the hospital determine which specialists, investigations and treatment facilities may be required.
WhatsApp GAF Healthcare on +91 90443 46292 for a records review. Use a local emergency department for urgent symptoms.
This page is intended for education and treatment planning and should not replace medical advice.
Sources
- National Cancer Institute (NCI) — Immunotherapy to Treat Cancer.
- National Cancer Institute — Immune Checkpoint Inhibitors.
- National Cancer Institute — T-Cell Transfer Therapy.
- National Cancer Institute — CAR T-Cell Research.
- European Society for Medical Oncology (ESMO) — Immunotherapy Side Effects.
- Cancer Research UK — Immunotherapy and Its Side Effects.
- Cancer Research UK — Checkpoint Inhibitors.
- Central Drugs Standard Control Organisation (CDSCO), India — Drug Approvals.
- Indian Council of Medical Research (ICMR) — Cancer management guidance.
- Multidisciplinary Indian medical-oncology and cellular-therapy practice.
Treatment Process
- 1
Share records
The patient provides pathology, immunohistochemistry, PD-L1 or MSI/MMR reports and imaging before anyone books travel.
- 2
Confirm the indication
A medical oncologist decides whether a checkpoint inhibitor, antibody, cellular therapy or no India list is the honest next step.
- 3
Review biomarkers
The team checks whether PD-L1, MSI/MMR or another marker is documented and whether the sample is still adequate.
- 4
Itemised estimate
GAF immunotherapy planning is $15,000–$45,000. Neighbouring checkpoint-inhibitor therapy is $18,000–$50,000 when that product is named.
- 5
Select the medicine
A checkpoint inhibitor, antibody or cellular therapy is chosen from the cancer biology, stage and evidence.
- 6
Start and monitor
Infusions begin with a written schedule for laboratory, thyroid, liver and immune-related-symptom checks.
- 7
Transfer home
Most checkpoint patients continue scheduled infusions at home after a stable plan is documented.
- 8
Review response
If the cancer progresses or toxicity is unacceptable, the team considers another systemic line or a different class of treatment.
